Liver X receptors are negative regulators of cardiac hypertrophy via suppressing NF-κB signalling

Cardiovascular Research

Volumn 84, Issue 1, 2009, Pages 119-126

  Wu, Sijie ^a,b   Yin, Ran ^c   Ernest, Rick ^d   Li, Yuquan ^a   Zhelyabovska, Olga ^a   Luo, Jinwen ^a,b   Yang, Yifeng ^b   Yang, Qinglin ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c JIANGXI MEDICAL COLLEGE   (China)

^d MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II; Cardiac hypertrophy; Cardiomyocytes; Inflammation; LPS; LXR ; LXR ; NF B

Indexed keywords

ANGIOTENSIN II; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; CELL RECEPTOR; DNA BINDING PROTEIN; FLUORINATED HYDROCARBON; LIVER X RECEPTOR; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE; SULFONAMIDE; TLR4 PROTEIN, MOUSE; TO-901317; TOLL LIKE RECEPTOR 4;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA COARCTATION; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; HEART LEFT VENTRICLE HYPERTROPHY; MALE; MOUSE; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; ADENOVIRUS; ANIMAL; C57BL MOUSE; CARDIOMEGALY; CELL CULTURE; DRUG ANTAGONISM; DRUG POTENTIATION; GENETICS; INFLAMMATION; METABOLISM; PHYSIOLOGY;

ADENOVIRIDAE; ANGIOTENSIN II; ANIMALS; CARDIOMEGALY; CELLS, CULTURED; DNA-BINDING PROTEINS; HYDROCARBONS, FLUORINATED; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; NF-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; SULFONAMIDES; TOLL-LIKE RECEPTOR 4;

EID: 70449706059     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp180     Document Type: Article

References (29)

1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med 1990;322:1561-1566.
2. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 2000;102:470-479.
3. Li Y, Ha T, Gao X, Kelley J, Williams DL, Browder IW et al. NF-kappaB activation is required for the development of cardiac hypertrophy in vivo. Am J Physiol Heart Circ Physiol 2004;287:H1712-H1720.
4. Higuchi Y, Chan TO, Brown MA, Zhang J, DeGeorge BR Jr, Funakoshi H et al. Cardioprotection afforded by NF-kappaB ablation is associated with activation of Akt in mice overexpressing TNF-alpha. Am J Physiol Heart Circ Physiol 2006;290:H590-H598.
5. Wu L, Iwai M, Li Z, Li JM, Mogi M, Horiuchi M. Nifedipine inhibited angio-tensin II-induced monocyte chemoattractant protein 1 expression: involvement of inhibitor of nuclear factor kappa B kinase and nuclear factor kappa B-inducing kinase. J Hypertens 2006;24:123-130.
6. Hong C, Tontonoz P. Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors. Curr Opin Genet Dev 2008;18:461-467.
7. Song C, Kokontis JM, Hiipakka RA, Liao S. Ubiquitous receptor: a receptor that modulates gene activation by retinoic acid and thyroid hormone receptors. Proc Natl Acad Sci USA 1994;91:10809-10813.
8. Teboul M, Enmark E, Li Q, Wikstrom AC, Pelto-Huikko M, Gustafsson JA. OR-1, a member of the nuclear receptor superfamily that interacts with the 9-cis-retinoic acid receptor. Proc Natl Acad Sci USA 1995;92: 2096-2100.
9. Willy PJ, Umesono K, Ong ES, Evans RM, Heyman RA, Mangelsdorf DJ. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev 1995;9:1033-1045.
10. Alberti S, Steffensen KR, Gustafsson JA. Structural characterisation of the mouse nuclear oxysterol receptor genes LXRalpha and LXRbeta. Gene 2000;243:93-103.
11. Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 1996;383:728-731.
12. Peet DJ, Turley SD, Ma W, Janowski BA, Lobaccaro JM, Hammer RE et al. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 1998;93:693-704.
13. Joseph SB, Bradley MN, Castrillo A, Bruhn KW, Mak PA, Pei L et al. LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell 2004;119:299-309.
14. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 2003;9:213-219.
15. Walcher D, Kummel A, Kehrle B, Bach H, Grub M, Durst R et al. LXR activation reduces proinflammatory cytokine expression in human CD4-positive lymphocytes. Arterioscler Thromb Vasc Biol 2006;26: 1022-1028.
16. Yasuda T, Kanno M, Kawamoto M, Yuge O, Ninomiya Y. Suppression of inducible nitric oxide synthase and cyclooxygenase-2 gene expression by 22(R)-hydroxycholesterol requires de novo protein synthesis in activated macrophages. J Steroid Biochem Mol Biol 2005;97:376-383.
17. Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 2006;116:607-614.
18. Thaik CM, Calderone A, Takahashi N, Colucci WS. Interleukin-1 beta modulates the growth and phenotype of neonatal rat cardiac myocytes. J Clin Invest 1995;96:1093-1099.
19. Laffitte BA, Joseph SB, Chen M, Castrillo A, Repa J, Wilpitz D et al. The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesions. Mol Cell Biol 2003;23: 2182-2191.
20. Laffitte BA, Repa JJ, Joseph SB, Wilpitz DC, Kast HR, Mangelsdorf DJ et al. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci USA 2001;98: 507-512.
21. Sadoshima J, Jahn L, Takahashi T, Kulik TJ, Izumo S. Molecular characterization of the stretch-induced adaptation of cultured cardiac cells. An in vitro model of load-induced cardiac hypertrophy. J Biol Chem 1992;267: 10551-10560.
22. Liu CJ, Cheng YC, Lee KW, Hsu HH, Chu CH, Tsai FJ et al. Lipopolysacchar-ide induces cellular hypertrophy through calcineurin/NFAT-3 signaling pathway in H9c2 myocardiac cells. Mol Cell Biochem 2008;313:167-178.
23. Wang YY, Dahle MK, Agren J, Myhre AE, Reinholt FP, Foster SJ et al. Activation of the liver X receptor protects against hepatic injury in endotox-emia by suppressing Kupffer cell activation. Shock 2006;25:141-146.
24. Cook SA, Novikov MS, Ahn Y, Matsui T, Rosenzweig A. A20 is dynamically regulated in the heart and inhibits the hypertrophic response. Circulation 2003;108:664-667.
25. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol 1998;274: R577-R595.
26. Gurevitch J, Frolkis I, Yuhas Y, Lifschitz-Mercer B, Berger E, Paz Y et al. Anti-tumor necrosis factor-alpha improves myocardial recovery after ischemia and reperfusion. J Am Coll Cardiol 1997;30:1554-1561.
27. Raymond RJ, Dehmer GJ, Theoharides TC, Deliargyris EN. Elevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction. Am Heart J 2001;141:435-438.
28. Fontaine C, Rigamonti E, Nohara A, Gervois P, Teissier E, Fruchart JC et al. Liver X receptor activation potentiates the lipopolysaccharide response in human macrophages. Circ Res 2007;101:40-49.
29. Imayama I, Ichiki T, Patton D, Inanaga K, Miyazaki R, Ohtsubo H et al. Liver X receptor activator downregulates angiotensin II type 1 receptor expression through dephosphorylation of Sp1. Hypertension 2008;51: 1631-1636.